These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 26535871)

  • 1. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
    Etienne G; Guilhot J; Rea D; Rigal-Huguet F; Nicolini F; Charbonnier A; Guerci-Bresler A; Legros L; Varet B; Gardembas M; Dubruille V; Tulliez M; Noel MP; Ianotto JC; Villemagne B; Carré M; Guilhot F; Rousselot P; Mahon FX
    J Clin Oncol; 2017 Jan; 35(3):298-305. PubMed ID: 28095277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
    Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
    Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
    Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
    Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Shin S; Kim JA; Kim HS; Cho EH; Kwak JY
    Leuk Res; 2012 Jun; 36(6):689-93. PubMed ID: 22398220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
    Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
    Takahashi N; Tauchi T; Kitamura K; Miyamura K; Saburi Y; Hatta Y; Miyata Y; Kobayashi S; Usuki K; Matsumura I; Minami Y; Usui N; Fukuda T; Takada S; Ishikawa M; Fujimaki K; Gomyo H; Sasaki O; Ohishi K; Miyake T; Imai K; Suzushima H; Mitsui H; Togitani K; Kiguchi T; Atsuta Y; Ohtake S; Ohnishi K; Kobayashi Y; Kiyoi H; Miyazaki Y; Naoe T;
    Int J Hematol; 2018 Feb; 107(2):185-193. PubMed ID: 28929332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
    Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
    Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
    Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
    Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Yeung DT; Dang P; Goyne JM; Slader C; Filshie RJ; Mills AK; Melo JV; White DL; Grigg AP; Hughes TP
    Blood; 2013 Jul; 122(4):515-22. PubMed ID: 23704092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
    Lee SE; Choi SY; Bang JH; Kim SH; Jang EJ; Byeun JY; Park JE; Jeon HR; Oh YJ; Kim HJ; Kim YK; Park JS; Jeong SH; Kim SH; Zang DY; Oh S; Koo DH; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Mauro MJ; Kim DW
    Am J Hematol; 2013 Jun; 88(6):449-54. PubMed ID: 23440689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
    Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
    In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.